title: Interferon-lambda: a new addition to an old family.
abstract: The discovery and initial description of the interferon-lambda (IFN-lambda) family in early 2003 opened an exciting new chapter in the field of IFN research. There are 3 IFN-lambda genes that encode 3 distinct but highly related proteins denoted IFN-lambda1, -lambda2, and -lambda3. These proteins are also known as interleukin-29 (IL-29), IL-28A, and IL-28B, respectively. Collectively, these 3 cytokines comprise the type III subset of IFNs. They are distinct from both type I and type II IFNs for a number of reasons, including the fact that they signal through a heterodimeric receptor complex that is different from the receptors used by type I or type II IFNs. Although type I IFNs (IFN-alpha/beta) and type III IFNs (IFN-lambda) signal via distinct receptor complexes, they activate the same intracellular signaling pathway and many of the same biological activities, including antiviral activity, in a wide variety of target cells. Consistent with their antiviral activity, expression of the IFN-lambda genes and their corresponding proteins is inducible by infection with many types of viruses. Therefore, expression of the type III IFNs (IFN-lambdas) and their primary biological activity are very similar to the type I IFNs. However, unlike IFN-alpha receptors which are broadly expressed on most cell types, including leukocytes, IFN-lambda receptors are largely restricted to cells of epithelial origin. The potential clinical importance of IFN-lambda as a novel antiviral therapeutic agent is already apparent. In addition, preclinical studies by several groups indicate that IFN-lambda may also be useful as a potential therapeutic agent for other clinical indications, including certain types of cancer.
authors: Division of Therapeutic Proteins, Center for Drug Evaluation and Research , Food and Drug Administration, Bethesda, Maryland 20892, USA. raymond.donnelly@fda.hhs.gov
authors: Raymond P
authors: RP
authors: Donnelly
authors: Sergei V
authors: SV
authors: Kotenko
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D004847:Epithelial Cells / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology; D014777:Virus Diseases / Q000188:drug therapy* / Q000276:immunology; D007378:Interleukins; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; C511668:interferon-lambda protein, mouse; D007378:Interleukins; D000095022:Interferon Lambda